Bosnalijek dd
Bosnalijek d.d. Sarajevo is the largest pharmaceutical manufacturer in Bosnia and Herzegovina, producing prescription, OTC, and dietary supplement products across cardiovascular, anti-infective, neurological, and respiratory categories. Founded in 1951, it is publicly listed on the Sarajevo Stock Exchange (BSNLR) and exports via FC Grand Capital to Russia.
- Company typePublic
- Founded1951
- HeadquartersSarajevo, Bosnia & Herzegovina
- Headcount—
- GTM typeB2C
- OfferingHardware or Manufacturing
What Bosnalijek dd does
Bosnalijek d.d. Sarajevo is the largest industrial pharmaceutical manufacturer in Bosnia and Herzegovina, founded in 1951 and headquartered at Jukićeva 53, Sarajevo. The company is publicly traded on the Sarajevo Stock Exchange under the ticker BSNLR and operates as a joint-stock company (dioničko društvo). Its product portfolio spans prescription medications, over-the-counter products, dietary supplements, antiseptics, and general-use pharmaceutical items across therapeutic areas including cardiovascular (BOSPYRIN PROTECT, TOZAR, AMLODIL, AMLOPRESSIN, ANGINAL, APIXA, AMINOL), anti-infectives (AZOMEX, DUOCLAV), antihistamines (ALERIX), neurological and psychiatric treatments (LUMINEL, MECOBALAMIN, LEVEX), musculoskeletal products (ALOPURINOL, PROMASS), dermatologicals (ARGEDIN, LYSODERM), and well-known OTC brands (DOLOREX, RHINOSTOP, LYSOBACT, LYNASE, ENTEROFURYL STOP, Royal Jelly, FeRAL, D3 SPRAY).
The underlying technology base is a GMP-compliant pharmaceutical manufacturing operation with quality control systems aligned to domestic and international Good Manufacturing Practice standards. The company supports healthcare professionals through the Vademaecum mobile application (iOS and Android), the 'Dnevna doza' (Daily Dose) professional journal with 34 published issues, and active participation in medical conferences such as the BHAAAS Days symposia. Branding is supported by a registered trademark portfolio covering at least 14 branded product lines.
Bosnalijek's revenue model is built on pharmaceutical product sales through two primary channels: domestic pharmacy and healthcare provider distribution across Bosnia and Herzegovina, and international export distribution led by its partnership with FC Grand Capital on the Russian pharmaceutical market. The company also runs a Russia representative office and maintains corporate investor relations, quarterly reports, and shareholder assemblies consistent with its SASE listing. Pricing is regulated by national healthcare authorities where applicable, and the company does not publicly disclose revenue or pricing details.
Bosnalijek dd firmographics
Firmographics- Name
- Bosnalijek dd
- Legal name
- Bosnalijek d.d. Sarajevo
- Website
- https://bosnalijek.ba
- Company type
- Public
- Founded year
- 1951
- Operating status
- Operating
- Short description
- Bosnalijek d.d. Sarajevo is the largest pharmaceutical manufacturer in Bosnia and Herzegovina, producing prescription, OTC, and dietary supplement products across cardiovascular, anti-infective, neurological, and respiratory categories. Founded in 1951, it is publicly listed on the Sarajevo Stock Exchange (BSNLR) and exports via FC Grand Capital to Russia.
- Ownership category
- akta.pro rank
Bosnalijek dd industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)
- akta.pro secondary industries
- Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF), OTC & Consumer Health Distributors (HLAIAJAC)
Keywords
Where Bosnalijek dd is headquartered
LocationHeadquarters
- HQ city
- Sarajevo
- HQ country
- Bosnia & Herzegovina
- HQ region
- Europe
Offices1 record
Markets served
Bosnalijek dd business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Distribution channels2 records
Marketing channels3 records
Bosnalijek dd product offering
Product offeringCore offering
Bosnalijek is a pharmaceutical manufacturer that produces a broad portfolio of prescription medications, over-the-counter (OTC) products, and dietary supplements. Its portfolio spans cardiovascular, anti-infective, neurological/psychiatric, respiratory, musculoskeletal, gastrointestinal, dermatological, and allergy therapeutic areas, along with general antiseptics and dietary supplements, manufactured in GMP-compliant facilities and distributed domestically in Bosnia and Herzegovina and in international export markets.
Product overview
Bosnalijek d.d. Sarajevo operates as a pharmaceutical company with a diverse portfolio of prescription medications, OTC products, and dietary supplements. The company produces products across multiple therapeutic areas including cardiovascular medications (cardiovascular system - e.g., AMLODIL, AMLOPRESSIN, ANGINAL, APIXA, BOSPYRIN PROTECT, TOZAR), anti-infectives (AZOMEX, DUOCLAV), antihistamines (ALERIX), neurological/psychiatric medications (LUMINEL, Mecobalamin), musculoskeletal treatments (ALOPURINOL BOSNALIJEK, PROMASS), dermatological products (ARGEDIN, Lysoderm), and general use products (ALKOSOL, ASEPTAN). The company also offers dietary supplements (Royal Jelly, FeRAL, D3 SPRAY, OPSTILAX), OTC medications for common conditions (Enterofuryl STOP, Rhinostop, Lysobact, DOLOREX), and maintains digital offerings including the Vademaecum mobile app and the Dnevna doza professional journal for healthcare workers. Bosnalijek's quality management system is aligned with domestic and international GMP standards.
Differentiator
Problem solved
Functional benefit
Brands
- Royal Jelly®: Royal jelly dietary supplement product line
- Alerix®
- Enterofuryl STOP®
- Rhinostop®
- Lysobact®
- Lynase®
- FeRAL®
- DOLOREX®
- Lysoderm®
- BOSPYRIN PROTECT
- TOZAR
- DUOCLAV
- LUMINEL
- MECOBALAMIN
- D3 SPRAY®
- Fenix NEO®
- LEVEX®
Products and services
- Royal Jelly
- Alerix
- Enterofuryl STOP
- Rhinostop
- Lysobact
- DOLOREX
- Lysoderm
- Bospyrin Protect
- Tozar
- Duoclav
- Luminel
- Azomex
- Cardiovascular prescription line (Amlodil, Amlopressin, Anginal, Apixa, Aminol)
- Alopurinol Bosnalijek
- Promass
- Altioks
- Argedin
- Alkosol and Aseptan antiseptics
- Lynase
- Fenix NEO
- FeRAL
- D3 SPRAY
- Mecobalamin
- Opstilax
- Vademaecum mobile application
- Dnevna doza (Daily Dose) professional journal
Companies that use Bosnalijek dd
Customer profileSegments2 records
Ideal customer profiles2 records
Bosnalijek dd technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Bosnalijek dd partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- FC Grand CapitalmajorFC Grand Capital is one of the leading distribution partners for Bosnalijek on the Russian pharmaceutical market. The partnership involves employees from Bosnalijek's Russia representative office meeting with FC Grand Capital representatives to strengthen international cooperation.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Bosnalijek dd competitors and assessment
Company assessmentDirect peers
- Galenika: Galenika is a Serbian pharmaceutical manufacturer with a broad generics and OTC portfolio. Comparable to Bosnalijek in scale, therapeutic breadth, and dependence on regional Western Balkans and CIS export markets.
- Hemofarm: Hemofarm is a major Serbian pharmaceutical manufacturer of generics and OTC products owned by STADA. Directly comparable to Bosnalijek as a regional Western Balkans pharma producer with similar generic/OTC portfolio mix and CEE export footprint.
- Alkaloid: Alkaloid is North Macedonia's largest pharmaceutical manufacturer, producing generics, OTC products, and cosmetics. Closely comparable to Bosnalijek as a regionally dominant pharma with branded portfolio and Southeast European distribution reach.
Broad incumbents
- KRKA: KRKA is a leading Slovenian generic pharmaceutical manufacturer with broad CEE/CIS distribution. Comparable to Bosnalijek in generic-and-OTC focus and Western Balkans presence, but materially larger and more diversified internationally.
- Teva Pharmaceutical: Teva is the world's largest generic drug manufacturer, active across CEE. Competes with Bosnalijek in core generic molecules (statins, antibiotics, cardiovascular) and OTC categories in Bosnia and Herzegovina and export markets.
- Lek (Sandoz): Lek is the Slovenian operating arm of Sandoz, the global generics leader. Directly comparable product overlap with Bosnalijek in cardiovascular, antibiotic, and OTC categories across the Western Balkans and CEE region.
- Gedeon Richter: Gedeon Richter is a major Hungarian pharmaceutical company with generics, branded products, and biosimilars. Comparable in regional CEE positioning and OTC presence, with broader product portfolio and stronger R&D pipeline than Bosnalijek.
- STADA Arzneimittel: STADA is a major European generics and consumer healthcare company. Comparable to Bosnalijek in OTC consumer health portfolio and CEE distribution; significantly larger and operates as a parent group of regional players like Hemofarm.
- Zentiva: Zentiva is a large European generics manufacturer with strong CEE presence. Overlaps with Bosnalijek in generic prescription medicines and OTC consumer health across Central and Eastern European markets.
Emerging players
- Alvogen: Alvogen is a US-headquartered generics company with strong Central and Eastern European operations. Comparable to Bosnalijek in CEE distribution reach and generic portfolio focus, though with broader geographic footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Bosnalijek dd social profiles
Digital presenceBosnalijek dd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bosnalijek dd leadership team
Management profileNumber of profiles
Bosnalijek dd funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bosnalijek dd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bosnalijek dd
What does Bosnalijek dd do?
Bosnalijek is a pharmaceutical manufacturer that produces a broad portfolio of prescription medications, over-the-counter (OTC) products, and dietary supplements. Its portfolio spans cardiovascular, anti-infective, neurological/psychiatric, respiratory, musculoskeletal, gastrointestinal, dermatological, and allergy therapeutic areas, along with general antiseptics and dietary supplements, manufactured in GMP-compliant facilities and distributed domestically in Bosnia and Herzegovina and in international export markets.
Is Bosnalijek dd a public or private company?
Bosnalijek dd is a public company. It is classified as public and is currently operating.
When was Bosnalijek dd founded?
Bosnalijek dd was founded in 1951.
Where is Bosnalijek dd based?
Bosnalijek dd is headquartered in Sarajevo, Bosnia & Herzegovina, in the Europe region.
Who are Bosnalijek dd's main competitors?
Direct peers on record are Galenika, Hemofarm and Alkaloid. Broad incumbents are KRKA, Teva Pharmaceutical, Lek (Sandoz), Gedeon Richter, STADA Arzneimittel and Zentiva. Alvogen is listed as an emerging player.
Does Bosnalijek dd have an API?
No public API is recorded for Bosnalijek dd.
What industry is Bosnalijek dd in?
Bosnalijek dd's product category is Pharmaceuticals. Its primary akta.pro industry code is CRADAMAD, Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges), with a secondary code of CRADAMAF, Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal). Its NAICS code is 325412 and its SIC code is 2834.